» Articles » PMID: 36409296

Plasma Levels of E-selectin Are Associated with Retinopathy in Sickle Cell Disease

Abstract

Background: The vascular endothelium is markedly disrupted in sickle cell disease (SCD) and is the converging cascade of the complex pathophysiologic processes linked to sickle cell vasculopathy. Circulating endothelial activation and/or apoptotic markers may reflect this endothelial activation/damage that contributes to the pathophysiology of the SCD vascular complications.

Methods: Plasmatic levels of circulating endothelial cells (CECs), E-selectin, progenitor's endothelial cells (EPCs), and circulating extracellular vesicles (EVs) were evaluated in 50 SCD patients, 16 with vasculopathy. The association between these markers and the occurrence of disease-related microvascular injuries of the eye (retinopathy), kidney (nephropathy), and skin (chronic active ulcers) was explored.

Results: Among the endothelial activation markers studied, only higher plasma levels of E-selectin were found in SCD patients with vasculopathy (p = .015). Increased E-selectin levels were associated with retinopathy (p < .001) but not with nephropathy or leg ulcers. All patients, at steady state, with or without vasculopathy, did not display a high count of CEC and EPC, markers of endothelial injury and repair. We did not show any significant differences in EVs levels between vasculopathy and not vasculopathy SCD patients.

Conclusions: Further studies will be required to determine whether the E-selectin could be used as an early biomarker of retinopathy sickle cell development.

Citing Articles

Selectins in Biology and Human Disease: Opportunity in E-selectin Antagonism.

Peterson J, Smith T, Rock E, Magnani J Cureus. 2024; 16(6):e61996.

PMID: 38983984 PMC: 11232095. DOI: 10.7759/cureus.61996.


Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy.

Ozer O, Dogan L, Baysal Z, Basir H, Ciftci A, Eroz P Graefes Arch Clin Exp Ophthalmol. 2024; 262(12):3787-3796.

PMID: 38976013 PMC: 11608169. DOI: 10.1007/s00417-024-06569-9.


Plasma levels of E-selectin are associated with retinopathy in sickle cell disease.

Agouti I, Masson E, Loundou A, Jean E, Arnaud L, Abdili E Eur J Haematol. 2022; 110(3):271-279.

PMID: 36409296 PMC: 10100354. DOI: 10.1111/ejh.13902.

References
1.
Niss O, Lane A, Asnani M, Yee M, Raj A, Creary S . Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. Blood Adv. 2020; 4(7):1501-1511. PMC: 7160281. DOI: 10.1182/bloodadvances.2019001378. View

2.
Platt O, Brambilla D, Rosse W, Milner P, Castro O, Steinberg M . Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-44. DOI: 10.1056/NEJM199406093302303. View

3.
Van Tuijn C, van Beers E, Schnog J, Biemond B . Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol. 2010; 85(7):532-5. PMC: 7159444. DOI: 10.1002/ajh.21731. View

4.
Gimbrone Jr M, Nagel T, Topper J . Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest. 1997; 99(8):1809-13. PMC: 508003. DOI: 10.1172/JCI119346. View

5.
Ataga K, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J . Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2016; 376(5):429-439. PMC: 5481200. DOI: 10.1056/NEJMoa1611770. View